By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Hepion Pharmaceuticals, Inc. insiders have been one-way buyers this past year: six people put roughly $1.2 million into the stock and nobody sold with their own money.
Biggest single buyer: LoPriore Vincent S, Chair, with roughly $400,000. That includes C-suite money, which tends to get the most attention.
1 investment managers listed HEPA in their latest 13F filings (Q2 2026); funds were split between buying and selling. Zooming out by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
Are insiders buying or selling HEPA stock?
In the last 12 months Hepion Pharmaceuticals, Inc. insiders made open-market purchases worth about $1.2 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in HEPA?
The most recent open-market insider trade in HEPA was filed on 2026-10-02.
How many institutions own HEPA?
1 investment managers reported holding HEPA in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded HEPA?
No congressional trades in HEPA were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).